Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
ARF6 (adenosyl diphosphate ribosylation factor 6) is a special subtype of the ARFs family and is widely expressed in tissues and organs such as brain, breast, liver, and prostate. It is mainly distributed in cell membranes and endosomes at the cellular level. ARF6 plays an important role in endocytosis, extracellular secretion, endosomal circulation, cell division, microvesicle trafficking and release, formation of intercellular adhesion junctions, and actin cytoskeletal remodeling. In addition, ARF6 is associated with the clathrin-dependent pathway and the clathrin-independent pathway of endocytosis, such as transferrin receptor, β2 adrenergic receptor, M2 cholinergic receptor, and cadherin.
In recent years, it has been found that ARF6 is highly expressed in various tumor tissues such as breast cancer, melanoma, glioma, lung cancer and prostate cancer, and is closely related to the invasion and metastasis of tumor cells. ARF6 mainly affects the invasion and migration ability of tumor cells through the following aspects: (1) Destruction of adhesion formation between tumor cells, promoting cell invasive phenotype, enhancing tumor cell movement and invasion ability; (2) Regulating cell muscle protein and cytoskeletal remodeling promotes the formation of synaptic structures associated with tumor cell migration and invasion, such as lamellipodia, membrane ruffles, and invadopodia; (3) Promoting the release of microvesicles containing various proteolytic enzymes in tumor cells, and enhance the ability of tumor cells to degrade extracellular matrix proteins.
Figure 1. A model of Arf6-mediated signals in cancer. (Li, et al. 2017).
ARF6 Regulates the Formation of Intercellular Adhesions
The correct establishment of intercellular adhesion junction plays a key role in maintaining the polarity of epithelial cells, and the destruction of intercellular adhesion junction is an important link for epithelial tumor cells to obtain invasion , migration phenotype, achieve tumor cell invasion, and metastasis. ARF6 inhibits cell-cell junctions and promotes tumor cell invasion and migration by regulating the expression and distribution of protein molecules associated with intercellular adhesions, including cadherin, catenin, and integrins.
Cadherin is the basis for the formation of adhesion junctions between epithelial cells and one of the polar marker proteins of epithelial cells. Under physiological conditions, ARF6 regulates the polarization of E-cadherin in polarized epithelial cells in the basement membrane and intracellular early interstitial, maintaining the dynamic stability of adhesion. Allaire et al. found that Rab35 is activated by acting on its downstream effector molecule, cyanidin-β2 [ACAP2 /centaurin - β2 (ACAP2 is ARF6-specific GAP)], inhibiting ARF6 activity and enhancing cadherin on tumor cell surface, promoting the expression level of intercellular adhesion junctions and inhibiting the invasion and migration of tumor cells. Xu et al. used siRNA interference technology and overexpression of ARF6 (T27N) to further confirm that EGF activates ARF6 in breast cancer cells mainly by promoting E-cadherin internalization of breast cancer cells, leading to destruction of intercellular adhesion junctions and enhancing invasion and migration ability of breast cancer cells.
β-catenin acts as a key molecule in the intercellular adhesion junction and forms a complex with cadherin to participate in the construction of cell adhesion junctions. ARF6 induces the depolymerization of β-catenin and cadherin complex by regulating β-catenin internalization, leading to destruction of intercellular adhesion junctions and enhancing tumor cell invasion. Grossmann et al found that WNT5A binds to the Frizzled 4 - LDL 6 complex in melanoma cells. Activation of intracellular ARF6 by GEP100 promotes the internalization of β-catenin, which leads to the depolymerization of β-catenin and N-cadherin complex, destroys the intercellular adhesion junction and enhances the invasion ability of tumor cells. The targeting factor SLIT2 binds to the melanoma cell surface receptor ROBO1, which can effectively inhibit ARF6 activity, thereby stabilizing the intercellular β-catenin and N-cadherin complex, and inhibit cell migration and invasion induced by ARF6 activation.
Intergrins are important molecules that recognize and adhere to each other between cells and extracellular matrix proteins. Enhancing the internalization of integrin and the circulation between the cell basement membrane and the serosa can significantly enhance the migration and invasive ability of tumor cells. It was found that β1 integrin, transferrin and major histocompatibility class I (MHCI) were co-localized in the circulating endosomes regulated by ARF6. ARF6 affects the invasion and migration of tumor cells by regulating intracellular integrin internalization and circulation.
ARF6 Regulates Cytoskeletal Remodeling
The formation of functional dendritic pseudopods on the cell adhesion surface is the first synaptic structure formed during tumor invasion and migration, and is also one of the important markers for tumor cells to obtain an invasive phenotype. Endogenous ARF6 is located in the dendritic pseudopodia of breast cancer and melanoma cells. Eades et al. found in breast cancer cells that ARF6 overexpression can be induced by inducing cell-invasive pseudopods, resulting in an invasive phenotype in non-invasive breast cancer MCF-7 cells. This suggests that ARF6-induced dendritic pseudopod formation plays an important regulatory role in the invasion of breast cancer cells. Marchesin et al. found that the ARF6 extremely active mutant ARF6 (T157N) was overexpressed in breast cancer MDA-MB-231 cells. Activation of ARF6 leads to enhanced Rac1 activity. Rac1 can increase the expression of intracellular actin monomer and activate pseudopodia on the surface of the membrane by activating Arp2 /3 and down-regulating the activity of F - actin depolymerization factor.
ARF6 Regulates Microvesicle Release
Studies have found that tumor cells can also degrade the extracellular matrix by releasing microvesicles containing multiple proteases from tumor cells to the surrounding cells and tissues, enhancing the invasion and migration ability of tumor cells and achieving distant invasion and metastasis of the tumor. The study found that there are microvesicles with positive ARF6 expression in human prostate cancer tissues. The expression of ARF6-positive microvesicles in peripheral blood of nude mice model of prostate cancer metastasis increase significantly compared with the control group, suggesting that ARF6 regulates the release of microvesicles from tumor cells and plays an important role in tumor invasion and migration.
Reference:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.